Also known as: Lipfendra
An oral peptide that lowers LDL cholesterol by blocking PCSK9.
Educational reference, not medical advice. Many compounds here are not approved, and products sold as research chemicals are not checked for purity. Plan any use with a licensed clinician.
How it works
PCSK9 inhibition lets the liver clear more LDL from the blood.
Evidence by goal
| Goal | Grade | What the grade means |
|---|---|---|
| Heart & circulation | A | Approved for this use or large randomized trials |
At a glance
- Route
- Oral tablet daily
- Half-life
- Not published
Reported dosing
20 mg once daily.
Timing: Once daily.
Cycle: Long-term.
From approved labels where they exist, otherwise from published trials and practitioner reports.
Side effects
- Diarrhea, dizziness (some patients)
Who should avoid it
- Pregnancy
Often combined with
Often with a statin.
Key findings
Lowered LDL by about 56 to 59%. Heart attack and stroke outcome data are still pending.
Where it is legal (Oct 2026)
| US | Prescription |
|---|---|
| Canada | Pending |
| Mexico | Not approved |
| EU | Pending |
Sources
Open Enlicitide in the Peptide Guide Compare all peptides by goal
Last reviewed November 2026. Regulatory status reflects the US unless noted and changes often.